Introduction {#Sec1_18}
============

The drastic rise in the number of publications on compounds from fungal endophytes within the past two decades is due to the creative ability of these fungi to produce secondary metabolites. There is also a rise in the need for new antibiotics, anti-malarial drugs, chemotherapeutic or pharmaceutical agents that are highly effective, possess low toxicity and have a minor environmental impact. The development of resistance in infectious microorganisms like *Staphylococcus*, *Mycobacterium* and *Streptococcus* to existing drugs and the presence of naturally resistant organisms are causing threat to mankind (Mwangi et al. [@CR55_18]; Hugonnet et al. [@CR39_18]; Richter et al. [@CR71_18]). Emerging diseases such as AIDS, SARS and NDM-1 necessitate the discovery and development of new drugs (Kumarasamy et al. [@CR46_18]). The weakened immune system due to AIDS not only requires specific drugs for treatment but also needs new therapies to combat the secondary problems arisen from it, and, furthermore, the HI virus is developing resistance towards the existing drugs (Richman et al. [@CR70_18]). Opportunistic pathogens such as *Aspergillus*, *Cryptococcus* and *Candida* are also virulent in immunocompromised patients, and in patients, who need an organ transplant. In addition, parasitic protozoan and nematodal infections such as malaria, leishmaniasis, trypanomiasis and filariasis are causing major problems in many countries and effective drugs against them are needed. Malaria is claiming more lives each year than diseases caused by any other infectious agent, with the exception of AIDS and TB (NIAID Global Health Research Plan for HIV/AIDS 2001), and enteric infections claim more lives of children each year than any other disease (Strobel et al. [@CR94_18]).

For all these reasons, there is a continuous search for novel natural products. The compounds produced by microorganisms have a history of offering opportunities for innovation in drug discovery and development, and therefore many scientists and researchers have turned their looks back to the microbial world. Exciting possibilities exist for those who are willing to take a risk and venture into the unexplored territories of the world to experience the excitement and thrill of engaging in the discovery of endophytes, their biology and potential usefulness (Strobel [@CR89_18]). In the past decade, endophytic microbes have attracted considerable attention as completely new sources of novel pharmaceuticals (Strobel [@CR88_18]).

A number of microbial metabolites have been available in quantities of up to hundreds of kilograms by fermentation technology (Grabley and Thiericke [@CR29_18]). From the screening of a huge number of microbial extracts, an unexpected diversity of natural compounds with a broad variety of biological activities has been found (Grabley and Sattler [@CR28_18]). Therefore, microorganisms associated with plants, rather than the plants themselves, can be raw material with promising therapeutic potential (Strobel [@CR88_18]). Until now, endophytic microbial metabolites have been studied for a wide range of activities like antioomycete, antibacterial, antifungal, anticancerous and immunosuppressive activities. Endophytes were given considerable credibility as sources of novel compounds through the discovery of Taxol^®^ biosynthesis, and a variety of other antibacterial, antifungal and anticancer metabolites from the endophytic fungi *Taxomyces andreae* and *Pestalotiopsis* spp. (Stierle et al. [@CR87_18]; Strobel [@CR89_18]). Endophytes can be used as sources of novel metabolites for medicine, agriculture and industrial uses. The best strategy for finding new bioactive compounds is to survey endophytes from plants restricted to special areas, as a means to isolate fungi that likely were never studied in earlier screening programs (Pelaez et al. [@CR59_18]).

Current Status of Endophyte Research with Respect to Drug Discovery {#Sec2_18}
===================================================================

The research on endophytes is growing enormously, as \>650 research articles covering both bacteria and fungi were published during the period between 1991 and 2010 ([www.sciencedirect.com](http://www.sciencedirect.com)) (Fig. [1](#Fig1_18){ref-type="fig"}). When the bibliographic search was restricted to endophyte and metabolite there were 253 published research articles, which shows that roughly 40% of the endophyte researchers were looking for secondary metabolites (Fig. [1](#Fig1_18){ref-type="fig"}). The potential of endophytic fungi as a source of novel drugs can be seen in terms of number of patents filed and granted on endophytes. When searched with the keyword endophyte (<http://www.freepatentsonline.com>) \>650 patents were filed and granted for using an endophyte as a source for new processes or industrial applications on bioactive metabolites.Fig. 1Number of publication on endophytes from 1990 to 2010 (data used from science direct with a keyword Endophyte + Metabolite). Two hundred and fifty three published articles were found from two decades of research on endophytic metabolites

Medicinal Plants {#Sec3_18}
================

The plant kingdom is a rich source of structural biodiversity offering a variety of natural products. Plants have been utilized to produce various types of medicines for thousands of years (Samuelsson [@CR77_18]). These medicines were initially used in the form of crude drugs such as tinctures, teas, poultices, powders and other herbal formulations (Balick and Cox [@CR7_18]; Samuelsson [@CR77_18]). More than 50,000 medicinal plants (Schippmann et al*.* [@CR78_18]) out of the total of 4, 22,000 flowering plants reported worldwide have been used for various medicinal purposes (Govaerts [@CR27_18]). The information on the plants usable for these purposes, and the methods of applying them for a particular ailment, were passed down orally through successive generations. Eventually the information on medicinal plants was recorded in herbals. More recently, the use of plants as medicines has focused on the isolation of active compounds, for example the isolation of morphine from opium poppy in the early nineteenth century (Kinghorn [@CR43_18]; Samuelsson [@CR77_18]). According to the World Health Organization (WHO [@CR114_18]), 80% of the world's population is dependent on health-care provided by medicinal plants.

A wide range of medicinal plant parts is used as extracts that can be considered raw drugs that possess specific medicinal properties. The different plant products used to cure various infectious diseases include root, stem, flower, fruit, root, twigs, exudates, and modified plant organs. Whereas some of these raw drugs are collected in small quantities for local use by the native communities and folk healers, many other raw drugs are collected in large quantities and traded in the market as the raw material for herbal industries (Uniyal et al*.* [@CR109_18]). The same medicinal plants provide a good source for isolation of endophytic fungi and screening for bioactive metabolites. In this way, the need to sacrifice plants that in some cases are rare or endangered can be avoided.

Endophytic Fungi {#Sec4_18}
================

Endophytic fungi are found practically in every plant species including terrestrial plants such as grasses (Bacon and White [@CR5_18]; Groppe et al. [@CR31_18]; Saikkonen et al*.* [@CR75_18]), palms (Taylor et al*.* [@CR100_18]; Frohlich et al*.* [@CR23_18]), banana (Brown et al*.* [@CR10_18]; Photita et al*.* [@CR64_18]), mangroves (Suryanarayanan et al*.* [@CR97_18]; Kumaresan and Suryanarayanan [@CR47_18]; Ananda and Sridhar [@CR1_18]) and halophytes (Suryanarayanan and Kumaresan [@CR96_18]), and in every subclass including mosses, liverworts, pteridophytes, gymnosperms and angiosperms (Provorov et al*.* [@CR68_18]). Endophytes are found in all plant tissues including seeds and ovules (Siegel et al*.* [@CR85_18]), fruits (Baayen et al*.* [@CR4_18]), stems (Gutierrez-Zamora and Martinez-Romero [@CR34_18]), roots (Germida et al*.* [@CR26_18]), leaves (Cannon and Simmons [@CR11_18]), inner bark of trees (Tejesvi et al. [@CR101_18], [@CR102_18]), tubers (Sturz et al*.* [@CR95_18]), buds (Pirttilä et al. [@CR66_18], [@CR67_18]; Ragazzi et al*.* [@CR69_18]), xylem (Hoff et al*.* [@CR37_18]) and rachis (Rodrigues and Samuels [@CR73_18]). Numerous publications are available on their biology (Jennings and Lysek [@CR41_18]; Clay [@CR13_18]; Brem and Leuchtmann [@CR9_18]; Arnold et al*.* [@CR3_18]), evolution (Carroll [@CR12_18]; Saikkonen et al*.* [@CR76_18]), occurrence (Kumar et al*.* [@CR45_18]; Tejesvi et al. [@CR102_18]), taxonomy (Petrini [@CR62_18]; Guo et al*.* [@CR32_18], [@CR33_18]) and biotechnological applications (Tomita [@CR107_18]; Strobel [@CR90_18]).

The impact of endophytic fungi on host plants is largely unknown compared with that of fungal pathogens or mycorrhizal symbionts. Endophytic fungi may influence other fungi present in the same host, existing between the tropical niches of pathogen and mutualist (Hoff et al. [@CR37_18]). This influence can be expressed directly by inhibition or stimulation of fungal growth, or indirectly via effects on host physiology and morphology. Thus, the genetic variability and unpredictability of pathogen interactions with the host plants can be attributed to endophytes (Saikkonen et al*.* [@CR74_18]; Hoff et al. [@CR37_18]).

Schulz et al. ([@CR81_18], [@CR82_18], [@CR83_18]) obtained \>6,500 endophytic isolates from different organs of more than 500 plants of diverse temperate habitats. The majority of the isolates belonged to ubiquitous genera (e.g. *Acremonium*, *Alternaria*, *Cladosporium*, *Coniothyrium*, *Epicoccum*, *Fusarium*, *Geniculosporium*, *Pestalotiopsis*, *Phoma*, *Pleospora*), concurring with previous results, reviewed by Petrini ([@CR62_18]), that many endophytes are from ubiquitous taxa. The assemblages of endophytes vary with habitat, as different ubiquitous genera are isolated from tropical than from temperate climates (e.g. see the chapters by M. Unterseher and T.S. Suryanarayanan, this volume). Some genera like *Fusarium, Phomopsis* and *Phoma* are common in both tropical and temperate climates, whereas members of Xylariaceae, *Colletotrichum*, *Guignardia*, *Phyllosticta* and *Pestalotiopsis* predominate in the tropics (Frohlich and Hyde [@CR22_18]; Cannon and Simmons [@CR11_18]; Suryanarayanan et al. [@CR98_18]; Arnold [@CR2_18]). An interesting aspect to investigate is how the occupation of an inter- or intracellular niche within a plant by one fungal group affects the subsequent establishment and evolution of other fungal partnerships (Schulz and Boyle [@CR80_18]).

Antimicrobials from Endophytic *Pestalotiopsis* Species {#Sec5_18}
=======================================================

*Pestalotiopsis* species have gained much attention in recent years as they produce many important secondary metabolites (Strobel [@CR88_18]; Tejesvi et al. [@CR103_18]; Xu et al. [@CR115_18]). At present, more than 30 *Pestalotiopsis* species have been reported as endophytes, there are 235 species listed in *Index Fungorum* (<http://www.indexfungorum.org/Names/Names.asp>) and they are usually found in tropical and subtropical plants throughout the world (Tejesvi et al*.* [@CR102_18], [@CR103_18]; Ding et al*.* [@CR19_18]; Liu et al*.* [@CR52_18]). A group of *Pestalotiopsis* species produces secondary metabolites, which have great potential as antioxidants, antimicrobials and anti-tumor compounds (Tan and Zou [@CR99_18]; Zhang et al*.* [@CR116_18]; Xu et al. [@CR115_18]). However, many endophytic *Pestalotiopsis* species have been unidentified due to the limitation and difficulty in applying classification based on existing morphological characters (Okane et al*.* [@CR58_18]; Suryanarayanan and Kumaresan [@CR96_18]; Suryanarayanan et al*.* [@CR97_18]; Toofanee and Dulymamode [@CR108_18]; Tejesvi et al. [@CR105_18]). There are \>140 metabolites that have been identified and characterized from *Pestalotiopsis* spp., belonging to different classes of compounds such as alkaloids, terpenoids, isocoumarin derivatives, coumarins, chromones, quinones, semiquinones, peptides, xanthones, xanthone derivatives, phenols, phenolic acids, and lactones (Fig. [2](#Fig2_18){ref-type="fig"}), of which some examples with antimicrobial activity are given in the following paragraph.Fig. 2Different class of secondary metabolite isolated from the genus *Pestalotiopsis*

The crude extract of the endophytic *Pestalotiopsis* sp. from the lichen *Clavarioides* sp. yielded six ambuic acid derivatives and a torreyanic acid (Fig. [3](#Fig3_18){ref-type="fig"}), which showed antibacterial activity against *Staphylococcus aureus* with IC~50~ values of 43.9 and 27.8 μM, respectively (Ding et al. [@CR19_18]). Ambuic acid has also been identified from different *P. microspora* strains isolated from *Taxus baccata*, *Torreya taxifolia*, *Taxodium disticum*, *Wollemia nobelis* and *Dendrobium speciosum* showing potential antifungal activity against plant pathogens (Li et al. [@CR50_18]). Three new caryophyllene-type sesquiterpene alcohols, 6-hydroxypunctaporonin E, 6-hydroxypunctaporonin B and 6-hydroxypunctaporonin A were isolated from culture filtrate of *P. disseminata*. The compounds 6-hydroxypunctaporonin E and 6-hydroxypunctaporonin B exhibited antibacterial activities in agar diffusion plate assays at 100 μg/disk against *Bacillus subtilis* (ATCC 6051) and *Staphylococcus aureus* (ATCC 29213) (Deyrup et al. [@CR16_18]). Pestalachloride A, an alkaloid isolated from an endophytic *Pestalotiopsis adusta*, displayed potent antifungal activity against *Fusarium culmorum* with an IC~50~ value of 0.89 μM (Li et al. [@CR51_18]). *Pestalotiopsis foedan*, isolated from the branches of an unidentified tree, yielded a novel spiroazaphilone derivative, pestafolide A, which exhibited antifungal activity against *Aspergillus fumigatus* (ATCC10894) (Ding et al. [@CR18_18]).Fig. 3Structures of bioactive metabolites produced by endophytic *Pestalotiopsis* spp.

Jesterone and hydroxy-jesterone are novel cyclohexenone epoxides isolated from a newly described endophytic fungal species *P. jesteri*, which was isolated from the bark of *Fragraea bodenii* (oak tree, family Loganiaceae) (Li and Strobel [@CR49_18]). Jesterone displayed selective antimycotic activity against the oomycetous fungi such as *Pythium ultimum*, *Aphanomyces* sp., *Phytophthora citrophthora*, *Phytophthora cinnamomi*, *Rhizoctonia solani*, and *Pyricularia oryzae* with MIC values of 94.7, 24.6, 94.7, 24.6, 94.7 and 94.7 μM, respectively (Li and Strobel [@CR49_18]). Bioassay-guided separation of the culture of *P. fici* yielded five new compounds, pestalofones A--E. Pestalofones C and D exhibited inhibitory effects against *Aspergillus fumigatus* with IC~50~/MIC values of 1.10/35.3, 0.90/31.2 μM, respectively (Liu et al. [@CR53_18]).

Two novel phenols, pestacin and isopestacin (Fig. [4](#Fig4_18){ref-type="fig"}) were isolated from *P. microspora* associated with the combretaceaous plant *Terminalia morobensis* (Strobel et al. [@CR93_18]; Harper et al. [@CR36_18]). Pestacin showed a moderate antifungal activity against *Pythium ultimum*, and isopestacin displayed moderate antimycotic activities against plant pathogenic oomycete *Pythium ultimum*, ascomycete *Sclerotinia sclerotiorum* and basidiomycete *Rhizoctonia solani* (Strobel et al. [@CR93_18]; Harper et al. [@CR36_18]). Pestaphthalides A and B having moderate antifungal activity were isolated from *P. foedan* of an unidentified tree near Dongzai, Hainan Province, China (Ding et al. [@CR18_18]). Pestalachlorides B and C are two chlorinated benzophenone derivatives isolated from endophytic *P. adusta*. Pestalachloride B exhibited antifungal activity against the fungal plant pathogen *Gibberella zeae* with an IC~50~ value of 1.1 μM (Li et al. [@CR51_18]). *Pestalotiopsis microspora* was isolated from *Torreya taxifolia* and it produced pestalopyrone, hydroxypestalopyrone and pestaloside phytotoxins in axenic cultures. Pestaloside exhibited broad-spectrum antifungal activity against the fungi *Cladosporium* sp., *Rhizoctonia solani*, *Geotrichum candidum* and *Agricus campestris* (Lee et al*.* [@CR48_18]).Fig. 4Timeline of discovery of important secondary metabolites produced by endophytic fungi

*Pestalotiopsis microspora* isolated from the inner bark of a small limb of Himalayan yew, *Taxus wallachiana* produces Taxol^®^ in mycelial culture. Taxol^®^ was identified by spectroscopic and chromatographic comparisons similar to authentic Taxol^®^ (Fig. [3](#Fig3_18){ref-type="fig"}). Optimal Taxol^®^ production occurred after 2--3 weeks in still culture at 23°C. ^14^C Acetate and ^14^C phenylalanine served as precursors for the fungal ^14^C Taxol^®^ (Strobel et al*.* [@CR91_18]). A number of unrelated fungal endophytes including *Pestalotia*, *Pestalotiopsis*, *Fusarium*, *Alternaria*, *Pithomyces*, *Monochaetia* also produce taxol in vitro (Strobel et al*.* [@CR92_18]).

Methods for Gaining Industry-Level Production Rates of Endophytic Metabolites {#Sec6_18}
=============================================================================

Industrial production of bioactive substances (e.g. pharmaceuticals, drugs) requires reproducible, dependable productivity. Microbial fermentation as a means of producing bioactive substances has several advantages: (1) If a microbe is the source organism, in an optimal case it can be grown in tank fermentors, producing an inexhaustible supply of material, (2) microorganisms typically respond favorably to routine culture techniques, whereas tissue culture or growing of plants requires either specialized techniques, or months of growth before harvesting is profitable, (3) product escalation is relatively easy in microorganisms. Various biosynthetic pathways can be optimized by changing the culture conditions for effective development and discovery of the lead compounds. For example, aplasmomycins were produced by *Streptomyces griseus* in the medium only after addition of NaCl (Nakamura et al. [@CR56_18]; Stierle and Stierle [@CR86_18]; Imada et al. [@CR40_18]).

Developing a productive microbial source for anti-infectives and immunosuppressants not only would lower the production cost of the compound but would also make it widely available. The sources of new drugs during the period from 1981 to 2006 indicate that over 60% of the drugs are natural products, and close to 70% of anti-infectives and 63% of anticancerous drugs are derived from natural products (Cragg and Newman [@CR14_18]). However, even though endophytic fungi show great potential as sources for industry-scale production of Taxol^®^, so far they have not been applied to industrial use (Ji et al. [@CR42_18]). Problems such as low fungal biomass produced during fermentation, low yield of Taxol^®^ in culture and lack of knowledge of regulation of the biosynthesis pathway limit the industrial use of these fungi (Ji et al. [@CR42_18]). A yield of 1 mg/l for Taxol^®^ production would be profitable at industrial scale, but the highest yields reported so far are 15 to 20 times lower (Deng et al. [@CR15_18]). Taxol^®^ has become a successful natural compound that is widely used as anti-tumor agent, with a higher demand than production rates. Therefore, knowledge of biotechnological tools for large-scale production of Taxol^®^ are needed to engineer endophytic strains, or to produce Taxol^®^ in heterologous hosts.

An endophytic organism can produce secondary metabolites in relatively high yield in culture, particularly when subjected to strain improvement programs (Penalva et al*.* [@CR60_18]). It is feasible to produce and isolate mutants that could readily be cultivated or could generate either additional products or modified products with a higher therapeutic index (Piepersberg [@CR65_18]). Moreover, the metabolites they produce are largely generated by enzymatic pathways that have the potential to biosynthetically link existing structures to chemical adjuncts in a reproducible manner, at yields that are acceptable for industrial scale (Verdine [@CR110_18]). To improve Taxol^®^ production, one strain of *Nodulisporium sylviform*, has been subjected to mutagenesis and production of 314--393 μg/L was obtained (Zhao et al. [@CR118_18]; Zhou et al. [@CR119_18]). Another way to modify the fungal secondary metabolome is to alter their epigenetic status (Williams et al. [@CR113_18]). By treating bioactive fungi with enzymes such as DNA methyltransferases or histone deacetylase inhibitors, enhanced chemical diversity can be obtained (Williams et al. [@CR113_18]). In this sense, natural products produced from microbes exhibit a number of properties that make them excellent candidates for industrial processes.

A typical problem encountered with endophytes is that they produce the bioactive metabolite only for a short while *in vitro* and then die during subculturing, or become impaired in production of the secondary metabolite, or do not grow at all *in vitro*. Similar problems encountered earlier with other microbes lead to the development of metagenomics and metatranscriptomics tools, to access the vast microbial wealth without restrictions of culturability or growth (Handelsman [@CR35_18]; Green and Keller [@CR30_18]; Bailly et al. [@CR6_18]). The culture independent analysis techniques such as terminal restriction fragment length polymorphism (T-RFLP) (Nikolcheva and Bärlocher [@CR57_18]), denaturing gradient gel electrophoresis (DGGE) (Duong et al. [@CR20_18]), or direct sequencing of ribosomal sequences (Seena et al*.* [@CR84_18]; Tejesvi et al. [@CR106_18]) are generally used for analyzing the diversity of unculturable fungal communities in plants. However, these methods are not suitable for functional studies of unculturable endophytes, and metagenomic and metatranscriptomic tools are still waiting to be applied to endophytes.

Another reasonably new and highly innovative approach is the biosynthesis of bioactive compounds in heterologous hosts. Heterologous expression of biosynthesis pathway of a compound through the transfer of the pathway genes from the producer organism to another, foreign host, can enable the production of the compound in higher quantities (Wenzel and Muller [@CR112_18]). *Escherichia coli* is a widely used host for expression of even complex metabolic pathways, such as that of erythromycin (Pfeifer et al. [@CR63_18]), echinomycin and triostin A (Watanabe [@CR111_18]). Other hosts used recently are e.g. *Myxococcus xanthus* and *Pseudomonas putida* for the production of epothilone or myxochromide S (Fu et al. [@CR24_18]), the thermopilic isolate *Corallococcus macrosporus* GT-2 for the production of myxochromide (Perlova et al. [@CR61_18]) and *Streptomyces lividans* for the production of meridamycin (Liu et al. [@CR54_18]). An engineered *Streptomyces avermitilis* mutant was developed very recently and used for the heterologous expression of three different biosynthesis pathways, streptomycin, cephamycin C and pladienolide. Another *Streptomyces* mutant was optimized for terpenoid production by introduction of a synthetic gene optimized for *Streptomyces* codon usage, and this mutant was capable of producing the plant terpenoid intermediate, amorpha-4,11-diene (Komatsua et al. [@CR44_18]). With respect to Taxol, already in [@CR38_18] Huang et al. accomplished in vivo production of the intermediate taxadiene in *E. coli*, and taxadiene and taxadien-5a-ol were produced in yeast by Engels et al. in [@CR21_18]. As for now, the production of Taxol itself in a heterologous host remains to be fulfilled. Yeast might be a promising host for such attempts, as the plant-derived artemisin has been successfully produced in yeast (Ro et al. [@CR72_18]). However, there is an on-going debate on the host selection between *E. coli* and yeast for the heterologous production of plant- and fungi-derived compounds. Although yeast might appear more suitable, there is a conflict of the yeast metabolism interacting with, and/or contaminating the expression of the heterologously introduced pathway (Zhang et al. [@CR117_18]). Another host that could become useful for the heterologous expression of endophytic products is *Aspergillus nidulans*. This host has been tested and used, e.g. for the heterologous production of Monacolin J (a lovastatin intermediate) (Zirkle et al. [@CR120_18]). As these methodologies develop further, and access to the genome data of endophytic fungi by pyrosequencing becomes available, further and most promising developments within this arena can be expected.

Drug Development Life Cycle {#Sec7_18}
===========================

The development of anti-infectives is known to take longer than that of the agrochemicals or industrial enzymes, because these compounds have to undergo three to four clinical studies. The drug development cycle from laboratory to market is long-lasting with the different phases involved, starting from drug discovery (for example, 10,000 compounds), preclinical trials (about 1--2% of the molecules), human clinical trials (2--5% of the molecules), Food and Drug Administration (FDA) or European Agency for the Evaluation of Medicinal Products (EMEA) review, FDA or EMEA approval and post-market clinical trials (Fig. [5](#Fig5_18){ref-type="fig"}). At the moment, the success rate for anti-infective molecules is about 16% for those approved between 1993 and 2004 (DiMasi et al. [@CR17_18]) and the time to reach the markets varies between 10 and 12 years, depending on the drug. Because antimicrobials have a short-lived nature as drugs, as they normally are taken only for short periods of time and easily develop resistance, the resulting low profit expectancy and, subsequently, a low interest by pharmaceutical companies complicate the efforts of developing completely new drug compounds (Bradley et al. [@CR8_18]). The pharmaceutical industry is therefore preferably investing in anti-inflammatory, ACE inhibitors, diabetes and anti-cancerous drugs, which are known to generate long-term revenue. Even though pharmaceutical and biotechnology companies are testing increasing numbers of compounds against various targets by high-throughput screening technologies, the question regarding drug development is whether the products can reach the markets in time for procurement of the disease. Regardless, or due to these problems, the efforts to look for safe, novel compounds from the nature should be persistent and continuous.Fig. 5The endophytes from ethnophamaceutically used plants as a source for new therapeutic leads

Conclusion {#Sec8_18}
==========

Endophytic fungi are prolific producers of secondary metabolites and *Pestalotiopsis* species, in particular, are of considerable interest to researchers and pharmacists due to their ability to synthesize a wide range of economically important bioactive molecules. The fermentation and high-throughput screening of a wide array of secondary metabolites with bioassay-guided fraction can yield various new metabolites for various therapeutic targets in the future. The new biotechnological tools have great promise in enabling the industrial use of endophytic fungi and their products. There is a continuous need for international co-operation to identify and develop antimicrobial drugs to combat various infectious diseases.
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